B
Bull
Bull · 25%TRML
$19.73
Szenariopreis
$47.980
0.000 (0.00%)Zum Schluss
Loading chart…
- High
- 48.000
- Open
- 47.980
- VWAP
- 47.99
- Vol
- 783.73K
- Mkt Cap
- —
- Low
- 47.980
- Amount
- 37.61M
- EV/EBITDA, TTM
- 0.00
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is pacibekitug (TOUR006), a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is focused on two strategic paths for TOUR006, the first of which is cardiovascular inflammation. Its second strategic path is thyroid eye disease (TED). TED is an autoimmune disease characterized by autoantibody-mediated activation of the tissues surrounding the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases.
Bewertungskennzahlen
The current forward P/E ratio for Tourmaline Bio Inc (TRML) is -4.85, compared to its 5-year average forward P/E of -6.44.
Alphio AI Price Scenarios for TRML
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding TRML
Event-Zeitleiste
News
4.010-29BenzingaCantor Fitzgerald Halts Overweight Rating for Tourmaline Bio
7.010-17PRnewswireSHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders
8.510-17GlobenewswireBRODSKY & SMITH INVESTOR ALERT: Announcing Investigations into Heidrick & Struggles International, Inc. (Nasdaq - HSII), Comerica Incorporated (NYSE - CMA), Veeco Instruments Inc. (Nasdaq - VECO), and Tourmaline Bio, Inc. (Nasdaq - TRML)
7.010-08GlobenewswireSHAREHOLDER RIGHTS NOTICE: Halper Sadeh LLC Probes TRML, CCRD, PBBK for Shareholder Advocacy
8.510-08GlobenewswireShareholder Update: Ongoing Class Action Investigation into Merger Involving TRML, PNFP, MRCC, and UNP
TRML FAQ — answered by Alphio AI
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is pacibekitug (TOUR006), a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is focused on two strategic paths for TOUR006, the first of which is cardiovascular inflammation. Its second strategic path is thyroid eye disease (TED). TED is an autoimmune disease characterized by autoantibody-mediated activation of the tissues surrounding the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases. It operates in the Healthcare sector.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.